- Home
- KOD vs OABI Comparison
KOD vs OABI Comparison
Compare KOD & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- OABI
- Stock Information
- Founded
- KOD 2009
- OABI 2012
- Country
- KOD United States
- OABI United States
- Employees
- KOD N/A
- OABI N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- OABI Health Care
- Exchange
- KOD Nasdaq
- OABI Nasdaq
- Market Cap
- KOD 454.7M
- OABI 388.5M
- IPO Year
- KOD 2018
- OABI N/A
- Fundamental
- Price
- KOD $7.50
- OABI $3.22
- Analyst Decision
- KOD Hold
- OABI Strong Buy
- Analyst Count
- KOD 4
- OABI 4
- Target Price
- KOD $8.00
- OABI $9.00
- AVG Volume (30 Days)
- KOD 448.1K
- OABI 448.8K
- Earning Date
- KOD 11-14-2024
- OABI 11-12-2024
- Dividend Yield
- KOD N/A
- OABI N/A
- EPS Growth
- KOD N/A
- OABI N/A
- EPS
- KOD N/A
- OABI N/A
- Revenue
- KOD N/A
- OABI $20,409,000.00
- Revenue This Year
- KOD N/A
- OABI N/A
- Revenue Next Year
- KOD N/A
- OABI $78.61
- P/E Ratio
- KOD N/A
- OABI N/A
- Revenue Growth
- KOD N/A
- OABI N/A
- 52 Week Low
- KOD $2.19
- OABI $3.16
- 52 Week High
- KOD $11.60
- OABI $6.55
- Technical
- Relative Strength Index (RSI)
- KOD 44.49
- OABI 32.70
- Support Level
- KOD $7.21
- OABI $3.16
- Resistance Level
- KOD $9.14
- OABI $3.29
- Average True Range (ATR)
- KOD 0.86
- OABI 0.13
- MACD
- KOD -0.33
- OABI -0.02
- Stochastic Oscillator
- KOD 15.73
- OABI 9.09
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.